Accession Number:

ADA459160

Title:

A Potent Oncolytic Herpes Simplex Virus for the Therapy of Advanced Prostate

Descriptive Note:

Annual rept. 1 Jul 2005-30 Jun 2006

Corporate Author:

BAYLOR COLL OF MEDICINE HOUSTON TX

Personal Author(s):

Report Date:

2006-07-01

Pagination or Media Count:

8.0

Abstract:

ONE OF THE MAJOR LIMITATIONS FACING THE THERAPEUTIC USE OF ONCOLYTIC VIRUSES INCLUDING ONCOLYTIC HSV IS THAT THE PRE-EXISTING ANTI-VECTOR IMMUNITY CAN SUBSTANTIALLY REDUCE THE INFECTIVITY OF THE VIRUS. WE PROPOSED IN THE AIM 3 OF THIS FUNDED PROJECT TO ADDRESS THIS ISSUE WITH TWO STRATEGIES 1 TO DELIVER ONCOLYTIC HSVS THROUGH LIPOSOME-FORMULATED VIRAL DNA INSTEAD OF THE TRADITIONAL VIRAL PARTICLES AND 2 TO USE T-LYMPHOCYTES AS A CARRIER FOR ONCOLYTIC HSV DELIVERY. IN TESTING THE FIRST STRATEGY OUR DATA DEMONSTRATED THAT VIRAL DNA FORMULATED WITH LIPOSOMES GAVE THE HIGHEST NUMBER OF PLAGUES. VIRAL CAPSIDS FORMULATED WITH LIPOSOME GAVE THE SECOND BEST RESULT. IN TESTING THE SECOND STRATEGY OUR RESULTS SHOWED THAT ONCOLYTIC HSV COULD BE EFFICIENTLY LOADED ONTO THE CARRIER CELLS USING A HITCHHIKE METHOD AND WAS THEN SUCCESSFULLY HANDED OFF TO THE TARGET CELLS. WE CONCLUDE THAT THIS HITCHHIKE STRATEGY REPRESENTS AVERY EFFICIENT WAY OF LOADING ONCOLYTIC VIRUS TO THE CARRIER CELLS WHICH ARE OTHERWISE NONPERMISSIVENESS TO INFECTION OF ONCOLYTIC HSVS.

Subject Categories:

  • Medicine and Medical Research
  • Microbiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE